Skip to main content
. 2014 Jun 20;5(14):5246–5256. doi: 10.18632/oncotarget.2124

Figure 1. Serum HGF levels change longitudinally in patients with SCLC undergoing chemotherapy.

Figure 1

(A) Baseline serum hepatocyte growth factor (sHGF) levels are elevated in SCLC patients when compared to healthy subjects. sHGF levels at diagnosis were measured in SCLC patients and healthy subjects using a ELISA kit. Box plot is displayed indicating sHGF levels in each group. sHGF medians are indicated below. Wilcoxon test was used for comparisons. (B) sHGF levels change in SCLC patients after treatment and at progression. Whole-blood samples were obtained from each SCLC patient during different disease stages (baseline, chemotherapy response assessment and progression). sHGF levels were determined by ELISA kit. Box plot is displayed indicating sHGF levels at different time points. sHGF medians are indicated below. Wilcoxon test was used for comparisons. (C) Graphs represent sHGF levels for each SCLC patient during different time points. Top: patients who show a decrease at response evaluation; bottom: patients who show an increase at response evaluation.